| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00259-010-1640-9 |
| P698 | PubMed publication ID | 21057787 |
| P50 | author | Raphaël Porcher | Q38640167 |
| Elif Hindié | Q47460841 | ||
| P2093 | author name string | Anne de Roquancourt | |
| Jacqueline Lehmann-Che | |||
| Marc Espié | |||
| Sylvie Giacchetti | |||
| David Groheux | |||
| Laetitia Vercellino | |||
| Jean-Luc Moretti | |||
| Caroline Cuvier | |||
| Anne-Sophie Hamy | |||
| P2860 | cites work | Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors | Q47705334 |
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. | Q51925963 | ||
| The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. | Q53472810 | ||
| Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. | Q53545742 | ||
| Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. | Q54024733 | ||
| Association between [ 18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation | Q63302054 | ||
| Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations | Q73080379 | ||
| High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases | Q73310506 | ||
| Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose | Q74608083 | ||
| [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy | Q80501660 | ||
| The relationship between FDG uptake in PET scans and biological behavior in breast cancer | Q80777346 | ||
| HER2 status and benefit from adjuvant trastuzumab in breast cancer | Q80959592 | ||
| The evolving role of PET/CT in breast cancer | Q84020615 | ||
| ??? | Q28262062 | ||
| Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen | Q21092375 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| TIGAR, a p53-inducible regulator of glycolysis and apoptosis | Q28118306 | ||
| Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up | Q28306437 | ||
| The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression | Q28609179 | ||
| p53 and metabolism | Q29617084 | ||
| Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. | Q31991133 | ||
| Gene expression patterns associated with p53 status in breast cancer. | Q33265626 | ||
| Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer | Q33845160 | ||
| 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis | Q34078191 | ||
| A simple p53 functional assay for screening cell lines, blood, and tumors | Q34397902 | ||
| Biological characterisation of breast cancer by means of PET. | Q35764576 | ||
| Triple negative breast cancers: clinical and prognostic implications. | Q37602289 | ||
| Revision of the American Joint Committee on Cancer staging system for breast cancer | Q38432706 | ||
| Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro | Q40235249 | ||
| High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors | Q42447874 | ||
| Prognostic markers in triple-negative breast cancer | Q42505075 | ||
| Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer | Q43167779 | ||
| Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography | Q43851417 | ||
| FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. | Q44149763 | ||
| Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography | Q44778014 | ||
| 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer | Q44820382 | ||
| Expression of glucose transporter GLUT-1 and estrogen receptors ER-alpha and ER-beta in human breast cancer | Q44978994 | ||
| 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. | Q45915234 | ||
| Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer | Q46152939 | ||
| Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures | Q46434753 | ||
| Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy | Q46457897 | ||
| Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer | Q46627140 | ||
| Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer | Q46648315 | ||
| Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors | Q46841949 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 426-435 | |
| P577 | publication date | 2010-11-06 | |
| P1433 | published in | European Journal of Nuclear Medicine and Molecular Imaging | Q15708890 |
| P1476 | title | Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. | |
| P478 | volume | 38 |
| Q38458792 | 18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study |
| Q50100711 | 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging |
| Q38446353 | 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes |
| Q52584340 | 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. |
| Q37566580 | 18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis |
| Q44456340 | Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer |
| Q26751999 | Application of positron emission tomography (PET/CT) in diagnosis of breast cancer. Part I. Diagnosis of breast cancer prior to treatment |
| Q38414263 | Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer |
| Q53517135 | Association between ¹⁸F-FDG uptake and molecular subtype of breast cancer. |
| Q84806666 | Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy |
| Q35211629 | Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma |
| Q46982856 | Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: a pilot study. |
| Q53093553 | Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT. |
| Q33683996 | CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients |
| Q47112640 | CONSORT-Independent prognostic value of asphericity of pretherapeutic F-18 FDG uptake by primary tumors in patients with breast cancer |
| Q64230448 | Can the Efficacy of [F]FDG-PET/CT in Clinical Oncology Be Enhanced by Screening Biomolecular Profiles? |
| Q60305761 | Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET/CT for prediction of tumor recurrence in breast cancer |
| Q53396296 | Concerning pretreatment ¹⁸F-FDG PET/CT imaging in patients with large or locally advanced breast cancer. |
| Q42376460 | Considering the Relationship between Quantitative Parameters and Prognostic Factors in Breast Cancer: Can Mean Standardized Uptake Value be an Alternative to Maximum Standardized Uptake Value? |
| Q38426713 | Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer |
| Q42102903 | Correlation between 18F-FDG Positron-Emission Tomography 18F-FDG Uptake Levels at Diagnosis and Histopathologic and Immunohistochemical Factors in Patients with Breast Cancer |
| Q48047542 | Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients |
| Q61809033 | Correlation of Maximum Standardized Uptake Values in 18F-Fluorodeoxyglucose Positron Emission Tomography-computed Tomography Scan with Immunohistochemistry and Other Prognostic Factors in Breast Cancer |
| Q48175913 | Correlation of Molecular Subtypes of Invasive Ductal Carcinoma of Breast with Glucose Metabolism in FDG PET/CT: Based on the Recommendations of the St. Gallen Consensus Meeting 2013. |
| Q35162694 | Correlation of Primary Tumor FDG Uptake with Clinicopathologic Prognostic Factors in Invasive Ductal Carcinoma of the Breast |
| Q38440214 | Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT. |
| Q58597805 | Correlation of tumor uptake on breast-specific gamma imaging and fluorodeoxyglucose PET/CT with molecular subtypes of breast cancer |
| Q47836759 | Deciphering metabolic rewiring in breast cancer subtypes |
| Q52986070 | Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer. |
| Q52986909 | Diffusion-weighted imaging and (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in breast cancer: Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors. |
| Q33576007 | Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? |
| Q41643948 | Dual-Time 18F-FDG PET/CT Imaging in Initial Locoregional Staging of Breast Carcinoma: Comparison with Conventional Imaging and Pathological Prognostic Factors. |
| Q93005499 | Dual-Time-Point FDG Uptake Correlates with Prognostic Factors of Invasive Breast Cancer: Clinical Usefulness of Early Delayed Scanning |
| Q45329633 | EJNMMI: the European way of communicating science |
| Q45023166 | Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla |
| Q93010229 | Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response |
| Q53261275 | Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim |
| Q53116763 | Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. |
| Q37407235 | Evaluation of the association between HIF-1α and HER-2 expression, hormone receptor status, Ki-67 expression, histology and tumor FDG uptake in breast cancer. |
| Q41075658 | FDG-PET/CT detection of very early breast cancer in women with breast microcalcification lesions found in mammography screening |
| Q52941027 | FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer. |
| Q43189620 | Fluorine-18 Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma: Correlation with Glucose Transporters and p53 Expression |
| Q33854382 | Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET. |
| Q37185872 | HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment |
| Q53074363 | HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. |
| Q90335058 | Hybrid 18F-FDG-PET/MRI Measurement of Standardized Uptake Value Coupled with Yin Yang 1 Signature in Metastatic Breast Cancer. A Preliminary Study |
| Q60926140 | Implications of reconstruction protocol for histo-biological characterisation of breast cancers using FDG-PET radiomics |
| Q37588160 | Initial Fludeoxyglucose (18F) Positron Emission Tomography-Computed Tomography (FDG-PET/CT) Imaging of Breast Cancer - Correlations with the Primary Tumour and Locoregional Metastases |
| Q55396783 | Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. |
| Q51727954 | Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer? |
| Q89737562 | Is there a difference in FDG PET findings of invasive ductal carcinoma of the breast with and without coexisting DCIS? |
| Q53148285 | Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy. |
| Q33685937 | Metabolic Radiomics for Pretreatment 18F-FDG PET/CT to Characterize Locally Advanced Breast Cancer: Histopathologic Characteristics, Response to Neoadjuvant Chemotherapy, and Prognosis |
| Q51008272 | Metabolic Tumor Burden Assessed by Dual Time Point [18F]FDG PET/CT in Locally Advanced Breast Cancer: Relation with Tumor Biology. |
| Q36104568 | Molecular Imaging in Breast Cancer: From Whole-Body PET/CT to Dedicated Breast PET. |
| Q42437926 | Molecular subtypes of breast cancer: metabolic correlation with ¹⁸F-FDG PET/CT. |
| Q35616275 | Noninvasive imaging of immune responses |
| Q36326057 | Oestrogen-related tumour phenotype: positron emission tomography characterisation with ¹⁸F-FDG and ¹⁸F-FES |
| Q36221080 | PET Tracers for Clinical Imaging of Breast Cancer. |
| Q46806270 | PET/CT and breast cancer subtypes. |
| Q51135004 | PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype |
| Q38863105 | Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer |
| Q34774840 | Positron Emission Tomography (PET) in Oncology |
| Q47856252 | Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer |
| Q37077266 | Predictive Ability of 18F-fluorodeoxyglucose Positron Emission Tomography/computed Tomography for Pathological Complete Response and Prognosis after Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Patients |
| Q38269204 | Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer |
| Q38687620 | Present and future role of FDG-PET/CT imaging in the management of breast cancer |
| Q92266023 | Prognostic Significance of Metabolic Parameters and Textural Features on 18F-FDG PET/CT in Invasive Ductal Carcinoma of Breast |
| Q33704628 | Prognostic Significance of Metabolic Tumor Volume Measured by (18)F-FDG PET/CT in Operable Primary Breast Cancer |
| Q36476568 | Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer |
| Q48444536 | Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. |
| Q53062665 | Prognostic impact of clinicopathological features and expression of biomarkers related to (18)F-FDG uptake in esophageal cancer. |
| Q55252177 | Quantification of FDG-PET/CT with delayed imaging in patients with newly diagnosed recurrent breast cancer. |
| Q58549843 | Quantitative assessment of metabolic tumor burden in molecular subtypes of primary breast cancer with FDG PET/CT |
| Q89244750 | Radiomics in Oncological PET/CT: Clinical Applications |
| Q93146161 | Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers |
| Q56516460 | Relationship between functional imaging and immunohistochemical markers and prediction of breast cancer subtype: a PET/MRI study |
| Q37697013 | Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer. |
| Q34795754 | Response prediction to neoadjuvant chemotherapy: comparison between pre-therapeutic gene expression profiles and in vitro chemosensitivity assay |
| Q38157648 | Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer |
| Q34657779 | Role of FDG PET-CT in evaluation of locoregional nodal disease for initial staging of breast cancer |
| Q38366386 | Role of imaging in neoadjuvant therapy for breast cancer. |
| Q36992771 | Spectrum of the Breast Lesions With Increased 18F-FDG Uptake on PET/CT. |
| Q53165455 | Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. |
| Q38403124 | Strong association of epidermal growth factor receptor status with breast cancer FDG uptake |
| Q93016071 | Targeting uptake transporters for cancer imaging and treatment |
| Q87998329 | The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer |
| Q39974510 | The Prognostic Value of (18)F-FDG PET/CT for Early Recurrence in Operable Breast Cancer: Comparison with TNM Stage |
| Q38411448 | The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase (18)F-FDG PET/CT. |
| Q37716473 | The impact of intratumoral metabolic heterogeneity on postoperative recurrence and survival in resectable esophageal squamous cell carcinoma |
| Q27300759 | The use of (18)F-2-fluorodeoxyglucose (FDG) to label antibody fragments for immuno-PET of pancreatic cancer |
| Q53114686 | To operate or to radiate: the added value of the maximal standardized uptake value in PET-FDG in cervical cancer patients. |
| Q37252097 | Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging |
| Q53043935 | Tumour and lymph node uptakes on dual-phased 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography/computed tomography correlate with prognostic parameters in breast cancer. |
| Q54545607 | Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. |
| Q35131272 | Utility of (18)F FDG-PET/CT for predicting prognosis of luminal-type breast cancer |
| Q89986543 | Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging for Prediction of Metastasis to Sentinel and Nonsentinel Nodes in Patients with Clinically Node-Negative Breast Cancer |
| Q35038626 | Utility of F-18 fluorodeoxyglucose posıtron emıssıon tomography/computed ın carcınoma of unknown primary |
| Q92053522 | Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study |
| Q38990326 | Voxelwise analysis of simultaneously acquired and spatially correlated 18 F-fluorodeoxyglucose (FDG)-PET and intravoxel incoherent motion metrics in breast cancer. |
| Q92401267 | Which of the fluorine-18 fluorodeoxyglucose positron emission tomography/computerized tomography parameters are better associated with prognostic factors in breast cancer? |
| Q89163356 | Whole-body 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) for staging locally advanced breast cancer: A prospective study from a tertiary cancer centre in south India |
| Q38677216 | [(18)F]FDG PET/CT features for the molecular characterization of primary breast tumors |
| Q38693888 | ¹⁸F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials |
| Q53089607 | ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. |
Search more.